Therapeutic genes for cancer gene therapy

Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology

Volumn 13, Issue 1, 1999, Pages 21-28

  Walther, Wolfgang ^a   Stein, Ulrike ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Cancer; Gene Therapy; Gene transfer; Therapeutic genes

Indexed keywords

CANCER THERAPY; CELL KILLING; GENE TARGETING; GENE THERAPY; GENE TRANSFER; MULTIDRUG RESISTANCE; REVIEW; SUICIDE GENE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

BACTERIA (MICROORGANISMS);

EID: 0033401038     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1385/MB:13:1:21     Document Type: Review

References (34)

1. 1. Colombo, M. P., Modesti, A., Parmiani, G., and Forni, G. Perspectives in cancer research: Local cytokine availability elicits tumor rejection and systemic immunity trough granulocyte-T-lymphocyte cross-talk. Cancer Res. 52, 1-5, 1992.
2. 2. Uckert, W. and Walther, W. (1994) Retrovirus-mediated gene transfer in cancer therapy. Pharmac. Ther. 63, 323-347.
3. 3. Allione, A., Consalvo, M., Nanni, P., Lollini, L., Cavallo F., Giovarelli, M., Forni, M., Gulino, A., Colombo, M. P., and Dellabona, P. (1994) Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL 10, tumor necrosis factor a, granulocyte-macrophage colony-stimulating factor, and g-interferon gene or admixed with conventional adjuvants. Cancer Res. 54, 6022-6026.
4. 4. Tepper, R. I. and Mulé, J. J. (1994) Experimental and clinical studies of cytokine gene-modified tumor cells. Hum. Gene Ther. 5, 153-164.
5. 5. Hock, H., Dorsch, M., Kuzendorf, U., Quin, Z., Diamantstein, T., and Blankenstein, T. (1993) Mechanism of rejection induced by tumor cell-targeted gene transfer of interleukin-2, interleukin-4, interleukin-7, tumor necrosis factor or interferon-gamma. Proc. Natl. Acad. Sci. USA 90, 2774-2778.
6. 6. McBride, W. H., Thacker, J. D., Comora, S., Economou, J. S., Keley, D., Hogge, D., Dubinett, S. M., and Dougherty, G. J. (1992) Genetic modification of a murine fibrosarcoma to produce interleukin-7 stimulates host cell infiltration and tumor immunity. Cancer Res. 52, 3931-3937.
7. 7. Tahara, H., Zitvogel, L. Storkus, W. J., Zeh, H. J., McKinney, T. G., Schreiber, R. D., Gubler, U., Robbins, P. D., and Lotze, M. T. (1995) Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol. 154, 6466-6474.
8. 8. Asher, A. L., Mulé, J. J., Kasid, A., Restifo, N. P., Salo J. L., Reichert, C. M., Jaffe, G., Fendly, B., Kriegler, M., and Rosenberg, S. A. (1991) Murine tumor cells transduced with the gene for tumor necrosis factor-a. J. Immunol. 146, 3227-3234.
9. 9. Walther, W., Fichtner, I., and Uckert, W. (1993) Retrovirus-mediated gene transfer of tumor necrosis factor alpha into colon carcinoma cells generates a growth inhibition. Anticancer Res. 13, 1565-1574.
10. 10. Steinmann, R. M. (1991) The dendritic cell system and its role in immunogenicity. Rev. Immunol. 9, 271-296.
11. 11. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, P., and Mulligan, R. C. (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophuge colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90, 3539-3543.
12. 12. Mackensen, A., Lindemann, A., and Mertelsmann, R. (1997) Immunostimulatory cytokines in somatic cells and gene therapy of cancer. Cytokine & Growth Factor Reviews 8, 119-128.
13. 13. Sobol, R. E., Fakhrai, H., Shawler, D., Gjerset, R., Dorigo, O., Carson, C., Khaleghi, T., Koziol, J., Shiftan, T. A., and Royston, I. (1995) Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther. 2, 164-167.
14. 14. Nabel, G. J., Nabel, E. G., Yang, Z. Y., Fox, B. A., Plautz, G. E., Gao, X., Huang, L., Shu, S., Gordon, D., and Chang, A. E. (1993) Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc. Natl. Acad. Sci. USA 90, 11307-11311.
15. 15. Moolten, F. L. and Wells, J. M. (1990) Curability of tumors bearing herpes thymidine kinase genes transferred by retrovirla vectors. J. Natl. Cancer Inst. 82, 287-300.
16. 16. Freeman, S. M., Aboud, C. N., Whartenby, K. A., Packman C. H., Koeplin, D. S., Moolten, F. L., and Abraham, G. N. (1993) The "bystander effect": tumour regression when a fraction of the tumour mass is genetically modified. Cancer Res. 53, 5274-5283.
17. 17. Sorscher, E. J., Peng, S., Bebo, Z., Allan, P. W., Bellett, L. L. Jr., and Parker, W. B.(1994) Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Ther. 1, 233-238.
18. 18. Mullen, C. A., Kilstrup, M., and Blease, M. (1992) Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. USA 89, 33-37.
19. 19. Mullen, C. A., Coale, M. M., Lowe, R., and Blease, M. (1994) Tumours eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumour. Cancer Res. 54, 1503-1506.
20. 20. Ramesh, R., Marrogi, A. J., Munshi, A., Abboud, C. N., and Freeman, S. M. (1996) In vivo analysis of the bystander effect: a cytokine cascade. Exp. Heamatol. 24, 829-838.
21. 21. Kuriyama, S., Kikukawa, M., Masui, K., Okuda, H., Nakatani, T., Sakamoto, T., Yoshiji, H., Fukui, H., Ikenaka, K., Mullen, C., and Tsuji, T. (1999) Cytosine deaminase/5-fluorocytosine gene therapy can induce efficient anti-tumor effects and protective immunity in immunocompetent mice but not in athymic nude mice. Int. J. Cancer 81, 592-597.
22. 22. Pope, I. M., Poston, G. J., and Kinsella, A. R. (1997) The role of the bystander effect in suicide gene therapy. Eur. J. Cancer 33, 1005-1016.
23. 23. Wei, M. X., Tamiya, T., Chase, M., Boviatsis, E. J., Chang, T. K., Kowall, N. W., Hochberg, F. H., Waxman, D. J., Breakfield, X. O., and Chiocca, E. A. (1994) Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B 1 gene. Hum. Gene Ther. 5, 969-978.
24. 24. Wills, K. N., Maneval , D. C., Menzel, P., Harris, M. P., Sutjipto, S., Vaillancourt, M. T., Huang, W. M., Johnson, D. E., Anderson, S. C., and Wen, S. F. (1994) Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum. Gene Ther. 5, 1079-1088.
25. 25. Roth, J. A. Nguyen, D., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Ferson, D. Z., Hong, W. K., Kowaki, R., Lee, J. J., Nesbitt, J. C., Pisters, K. M., Putnam, J. B., Schea, R., Shin, D. M., Walsh, G. L., Dolormente, M. M., Han, C. I., Martin, F. D., Yen, N., Xu, K., Stephens, L. C., McDonnell, T. J., Mukhopadhyay, T., and Cai, D. (1996) Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med. 2, 985-991.
26. 26. Habib, N. A., Ding, S.-F., El-Masry, R., Mitry, R. R., Honda, K., Michail, N. E., Dalla-Serra, G., Izzi, G., Greco, L., Bassyouni, M., El-Thonkhy, M., and Abdel-Gaffar, Y. (1996) Preliminary report: the short-term effects of direct p53 DNA injectionin primary hepatocellular carcinomas. Cancer Detect. & Preven. 20, 103-107.
27. 27. Mukhopadhyay, T., Tainsky, M., Cavender, A. C., and Roth, J. A. (1991) Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res. 51, 1744-1748.
28. 28. Georges, R. N., Mukhopadhyay, T., Zhang, Y., Yen, N., and Roth, J. A. (1993) Prevention of orthotopic human lung cancer growth by intratracheal installation of a retroviral antisense K-ras construct. Cancer Res. 53, 1743-1746.
29. 29. Koizumi, M, Kamiya, H., and Othsuka, E. (1992) Ribozymes designed to inhibit transformation of NIH 3T3 cells by the activated c-H-ras gene. Gene 117, 179-184.
30. 30. Kashani-Sabet, M., Funato, T., Tone, T., Jiao, L., Wang, W., Yoshida, E., Kashfinn, B. I., Shitara, T., Wu, A. M., and Moreno, J. G. (1992) Reversal of the malignant phenotype by an anti-ras ribozyme. Antisense Res. Dev. 2, 3-15.
31. 3 1. Dorigo, O., Turla, S. T., Lebedeva, S., and Gjerset, R. A. (1998) Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function. J. Neurosurgery 88, 535-540.
32. 32. O'Connor, P. M., Jackman, J., Jondle, D., Bhatia, K., Magrath, I., and Kohn, K. W. (1993) Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensilivity of Burkitt's lymphoma cell lines. Cancer Res. 53, 4776-4780.
33. 33. Roth, J. A. (1996) Clinical protocol: modification of tumor suppressor gene expression and induction of apoplosis in non-small cell lung cancer (NSCLC) with an adenovirus vector expressing wild-type p53 and cisplatin. Hum. Gene Ther. 7, 1013-1030.
34. 34. Deisseroth, A. B., Holmes, F., Hortobagyi, G., and Champlin, R. (1996) Use of safely-modified retro-virus to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of breast cancer: a pilot trial. Hum. Gene Ther. 7, 401-416.